EGFR and non-small cell lung carcinoma: EGFR assays on cfDNA biopsies routinely allow physicians to detect targetable or prognostic somatic alterations at early stages such as in peri-operative contexts, and in residual disease for patients with NSCLC following treatment with curative intent [23].